Hemophilia A With Inhibitors
9
0
0
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
22.2%
2 terminated out of 9 trials
71.4%
-15.1% vs benchmark
33%
3 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa
Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors
International Immune Tolerance Study
The Malmö International Brother Study (MIBS)